Empoli
Generic Name
Empagliflozin
Manufacturer
Acme Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| empoli 25 mg tablet | ৳ 50.00 | ৳ 500.00 |
Description
Overview of the medicine
Empagliflozin is an oral antidiabetic drug used to improve glycemic control in adults with type 2 diabetes mellitus. It also reduces the risk of cardiovascular death, hospitalization for heart failure, and progression of kidney disease in specific patient populations.
Uses & Indications
Dosage
Adults
The recommended initial dose is 10 mg once daily. For additional glycemic control and cardiovascular/renal benefits, the dose may be increased to 25 mg once daily.
Elderly
No dose adjustment is required based on age alone. Renal function should be monitored.
Renal_impairment
Initial dose 10 mg once daily. Not recommended to initiate if eGFR is <20 mL/min/1.73m². Continue 10 mg or 25 mg if eGFR falls below 20 mL/min/1.73m² if already on therapy.
How to Take
Take orally once daily in the morning, with or without food. Swallow the tablet whole with water.
Mechanism of Action
Empagliflozin selectively inhibits the sodium-glucose co-transporter 2 (SGLT2) in the renal tubules, reducing glucose reabsorption and increasing glucose excretion in the urine. This leads to a reduction in blood glucose levels independently of insulin.
Pharmacokinetics
Onset
Within 30-60 minutes.
Excretion
Approximately 50% renally excreted, 50% fecally excreted.
Half life
Approximately 12.4 hours.
Absorption
Rapidly absorbed after oral administration, peak plasma concentrations reached in 1.5 hours.
Metabolism
Primarily metabolized by glucuronidation in the liver.
Side Effects
Contraindications
- Hypersensitivity to empagliflozin or any excipients of the tablet.
- Patients on dialysis.
Drug Interactions
Lithium
SGLT2 inhibitors may decrease serum lithium concentrations.
Diuretics
May increase the risk of dehydration and hypotension.
Insulin and Insulin Secretagogues (e.g., sulfonylureas)
May increase the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
In case of an overdose, immediately seek medical attention. Symptomatic and supportive treatment should be initiated as appropriate.
Pregnancy & Lactation
Not recommended during pregnancy due to potential for renal developmental abnormalities in the second and third trimesters. It is unknown if empagliflozin is excreted in human milk; use is not recommended during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to empagliflozin or any excipients of the tablet.
- Patients on dialysis.
Drug Interactions
Lithium
SGLT2 inhibitors may decrease serum lithium concentrations.
Diuretics
May increase the risk of dehydration and hypotension.
Insulin and Insulin Secretagogues (e.g., sulfonylureas)
May increase the risk of hypoglycemia. A lower dose of insulin or sulfonylurea may be required.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
In case of an overdose, immediately seek medical attention. Symptomatic and supportive treatment should be initiated as appropriate.
Pregnancy & Lactation
Not recommended during pregnancy due to potential for renal developmental abnormalities in the second and third trimesters. It is unknown if empagliflozin is excreted in human milk; use is not recommended during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months from manufacturing date.
Availability
Available in pharmacies worldwide
Approval Status
Approved by FDA, DGDA (Bangladesh)
Patent Status
Patent protected (brand name)
Clinical Trials
Key trials include EMPA-REG OUTCOME (cardiovascular safety), EMPEROR-Reduced and EMPEROR-Preserved (heart failure), and EMPA-KIDNEY (chronic kidney disease).
Lab Monitoring
- Renal function (eGFR) before initiation and periodically thereafter.
- Serum electrolytes, particularly in patients at risk for volume depletion.
- Blood glucose levels regularly.
Doctor Notes
- Assess renal function (eGFR) before initiating and during treatment.
- Educate patients on symptoms of DKA, UTIs, and genital infections.
- Consider temporary discontinuation in situations associated with volume depletion or acute kidney injury.
Patient Guidelines
- Stay well-hydrated to reduce the risk of dehydration and kidney problems.
- Monitor blood sugar regularly as advised by your doctor.
- Be aware of symptoms of urinary tract infections (UTIs) or genital yeast infections and report them to your doctor.
- Seek immediate medical attention if you experience symptoms of diabetic ketoacidosis (DKA) such as nausea, vomiting, abdominal pain, excessive thirst, difficulty breathing, or unusual fatigue.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not take a double dose.
Driving Precautions
Empagliflozin alone is not associated with hypoglycemia. However, when used in combination with insulin or sulfonylureas, it may increase the risk of hypoglycemia which can impair driving ability. Exercise caution.
Lifestyle Advice
- Maintain a balanced diet and regular exercise routine as part of your diabetes management plan.
- Avoid excessive alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Empoli Brand
Other medicines available under the same brand name
